Abstract
GVHD continues to be a major complication after allogeneic hematopoietic stem cell transplantation even when the recipient is given immunosuppression for the prophylaxis of this severe disease. There have been many advances in the prevention and treatment of GVHD, using compounds such as cyclosporine, FK506, mycophenolate mofetil or monoclonal IL-2 receptor antagonist. New strategies seem to include sequential therapy involving the blocking of both endogenous cytokines and alloreactive donor cells. However, further clinical and laboratory studies are needed in order to improve the therapy of established GVHD. Bone Marrow Transplantation (2000) 25 , Suppl. 2, S12–S15.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Basara, N., Blau, I., Willenbacher, W. et al. New strategies in the treatment of graft-versus-host disease. Bone Marrow Transplant 25 (Suppl 2), S12–S15 (2000). https://doi.org/10.1038/sj.bmt.1702345
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702345
Keywords
This article is cited by
-
Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors
Bone Marrow Transplantation (2004)
-
Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation
Bone Marrow Transplantation (2004)
-
Suicide-Gene-Transduced Donor T-Cells for Controlled Graft-versus-Host Disease and Graft-Versus-Tumor
International Journal of Hematology (2002)
